Stock drives before opening:
Virus Treatments (NASDAQ:) 63% less; Announced preliminary results from the FORTRESS study (Fibromyalgia Outcomes Research Trial to Evaluate Synergistic Suppression of Herpes Simplex Virus-1 (HSV-1)) on oral IMC-1 for FM therapy. Overall, the FORTRESS study did not achieve statistical significance on the pre-specified primary efficacy end point of change from baseline to week 14 in the weekly mean of self-reported daily average pain intensity scores comparing IMC-1 to placebo (p = 0.302) . However, analysis of the data indicates a ramification of the response based on the timing of patient enrollment into the FORTRESS trial. During the first half of the trial (June 2021 to November 2021), for patients enrolled (n = 208) when the delta variant of COVID-19 was the predominant strain in the United States, IMC-1 showed no improvement versus placebo-treatment. The patients.
Purple Innovation, Inc. (NASDAQ 🙂 44% higher; It confirmed that on September 17, 2022 it had received a non-binding, non-binding offer from Coliseum Capital Management, LLC to acquire all of Purple’s outstanding capital stock for $4.35 per share.
BioLineRx Ltd. (NASDAQ:) 32% less; It has definitive agreements with various institutional investors for the issuance and sale in a registered direct offering of 13,636,365 of the Company’s American Depository Shares (ADS) and secured purchase of up to a total of 13,636,365 ADS, at a combined purchase price of $1.10 per advertisement. and the associated note. Each ADS represents fifteen (15) ordinary shares.
knowledge 4 Inc (NASDAQ:) 30% higher; Receiving a non-binding offer from Vista Equity Partners Management, LLC to acquire all outstanding shares of KnowBe4 not already owned by Vista for $24.00 per share, payable in cash.
Allakos Inc. (NASDAQ 🙂 12% higher; announced the pricing of the underwritten offer of 29,882,000 shares of its common stock at an offer price of $5.02 per share.
broad wind power Inc (NASDAQ:) 9% higher; announced that the company has received $38 million in new tower orders from a leading global wind turbine manufacturer.
Wix.com (NASDAQ:) 6% higher; Active hedge fund Starboard Value confirmed a 9% stake.
Bluebird Bio Company (NASDAQ:) 6% higher; The US Food and Drug Administration (FDA) has announced that it has granted accelerated approval for SKYSONA® (elivaldogene autotemcel), also known as eli-cel, to slow the progression of neurological dysfunction in boys 4 to 17 years of age with early active cerebral adrenal dystrophy. (Cald). The company also confirmed that a previous clinical ban on the eli-cel clinical development program has been lifted.
Take-Two Interactive. interactive Software (NASDAQ:) 3% less; A major leak has shown more than 90 videos of the blockbuster Grand Theft 6 movie.
AutoZone (NYSE:) 3% higher; Q4 EPS reported $40.51, $2.00 better than analysts’ estimates of $38.51. Revenue for the quarter came in at $5.3 billion versus the consensus estimate of $5.15 billion.